[Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
date : 6/18/2024
The English version of the file has been published. (June 18, 2024)
Health and Global Policy Institute (HGPI) has offered policy recommendations and taken a number of other activities to promote patient and public involvement (PPI) in policy development process, under our stated mission of “Achieving citizen-centered health policy.” Recently, initiatives for PPI in processes of health policy development are now being advanced at both the national Government and local level at councils. However, new issues have been recognized consequently, which include lack of the diversities in and the number of individuals who desire to be involved. Based on our recognition of these issues, our PPI Support Project this fiscal year aims to promote the involvement of diverse patient and public representatives into policy development process.
Based on our discussions to date, we have compiled a ” Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government.” This guidance reviews how PPI in the policymaking process is important and outlines the initiatives that are required in the future to promote it. Please refer to the PDF file at the end of this document for the details of this guide.
FY2023 Advisory Board Members (Titles omitted; in Japanese alphabetical order by last name, absent members included)
Kyoko Ama (Representative, Children and Healthcare Project; Fellow, HGPI)
Shinsuke Amano (Chair, The Japan Federation of Cancer Patient Groups; CEO, Group Nexus Japan)
Etsuko Aruga (Professor, Department of Palliative Medicine, Teikyo University School of Medicine)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Takeshi Shukunobe (President and CEO, PPeCC)
Kazuyuki Suzuki (Senior Lead, Patient Engagement Group, Strategy & Execution, Novartis Pharma K.K.)
Yasuhiro Sensho (CEO, SENSHO-GUMI, Co., Ltd.; Former Director-General, MHLW)
Teppei Maeda (Lawyer, Maeda & Unosawa Law Offices; Representative, Medical Basic Act Community)
Kaori Muto (Professor, Department of Public Policy Studies, Institute of Medical Science, University of Tokyo)
Akira Morita (Representative Director, Next Generation Fundamental Policy Research Institute (NFI))
Ikuko Yamaguchi (Chief Director, Consumer Organization for Medicine and Law (COML))
Risa Yamazaki (Public Affairs Group, External Affairs Department, Chugai Pharmaceutical Co., LTD.)
Project sponsors (in Japanese alphabetical order)
National Graduate Institute for Policy Studies (GRIPS) Global Health Innovation Policy Program
Syneos Health Commercial K.K.
Chugai Pharmaceutical Co., Ltd.
Novartis Pharma K.K.
Guidance/brochure
| Guidance | Brochure | |
| For Web | For Print Please print in landscape orientation, double-sided (short edge binding), and fold in half. |
|
![]() |
![]() |
![]() |
Top Research & Recommendations Posts
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Policy Recommendations] Recommendations on Strategic Investments in Policies for Brain Health to Revitalize Japan: Hopes for the New Administration (December 1, 2025)
- [Announcement] HGPI Endorses the “Belém Health Action Plan” (November 14, 2025)
- [Announcement] HGPI Joins Global Green and Healthy Hospitals (August 1, 2023)
- [Research Report] AMR Policy Update #2: WHO’s First Report on Fungal Infection—Bridging the Gap Between Clinical Practice and R&D
Featured Posts
-
2025-12-09
[Event Report] Special Seminar “Rising to New Challenges in Health Sciences for Future Society: Novel Developments in the Field of Epilepsy in Japan and Globally” Belgium Pavilion Special Seminar, World Expo 2025 Osaka, Kansai (September 18, 2025)
-
2025-12-11
[Event Report] Core Components of Universal Health Coverage (UHC): Achieving “Healthcare Without Financial Hardship” in Asia-Pacific and Japan (December 5, 2025)
-
2025-12-12
[Registration Open] Meaningful Involvement Promotion Project Urgent Symposium “The New Takaichi Administration and Central Social Insurance Medical Council Reform – Ensuring Patients’ Voices are Heard” (January 22, 2026)
-
2025-12-12
[Registration Open] (Webinar) The 140th HGPI Seminar “Early Detection to Reduce COPD Disease Burden: Connecting Clinical Frontiers with Health Policy” (January 27, 2026)
-
2025-12-16
[Discussion Points] Policy Dialogue “Considering Comprehensive Genomic Profiling from the Perspective of Patient Access: Utilizing the Medical Service Fee Reimbursement System and the Mixed Medical Services Program to Meet the Needs of Today” (November 28, 2025)





